Replies to post #250906 on Biotech Values

[jbog]

CEO, Mark Foley is buying 30,000 shares via the offering

This seems to be common now. Two weeks ago Rothbaum bought $25 million worth of Iova's offering while two more directors bought $3 million and $500K worth shortly thereafter.

Rothbaum's $25 mil is now worth $50 mil in less than 2 weeks. Rothbaum has bought 20 million shares over the last 14 months priced at $5, $6 and $9.

[Biowatch]

Ouch. So Foley benefits while the average investor watches it drop again.

…based on today's offering the upside to this figure is probably less than what I originally expected.

It seems a cheap price to raise $108 million* if everything is going well.

[dewophile]

“Will RVNC now decline the third $100M tranche of the Athyrium Capital loan”

I thought it was amended to 150M (second tranche decreased to 50M)

I have no idea but would lean toward them probably taking the loan if they can. They have to fund therapeutics launch and ideally some further development in therapeutics (unless they really feel they can get meaningful off label limb spasticity)